nach oben

Lasers in Medical Science

Erschienen in:

06.01.2022 | Original Article

The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM)

verfasst von: Kun-Ling Lin, Shih-Hsiang Chou, Zi-Xi Loo, Yi-Yin Liu, Jung-Chien Cheng, Cheng-Yu Long

Erschienen in: Lasers in Medical Science | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

The purpose of our study was to investigate the effects of vulvovaginal erbium laser on the genitourinary syndrome of menopause (GSM) and sexual function of postmenopausal women. We conducted a retrospective study of sixty-four postmenopausal women with GSM, and these patients were scheduled for three times of vulvovaginal erbium laser treatment. A baseline and post-treatment vaginal status was assessed by measuring vaginal pH, patients’ subjective vulvovaginal atrophy (VVA) symptoms, which included dryness, dyspareunia, itching, and burning. The urinary response to treatment was assessed using ICIQ-SF, UDI-6, IIQ-7, OABSS, and POPDI-6. Sexual function was evaluated using the Female Sexual Function Index (FSFI) before and after vulvovaginal laser therapy. Patient follow-ups were scheduled for 12 months after treatment. A total of sixty-four patients were enrolled in the study. We observed the significant improvement in the percentage of negative symptoms (dryness/dyspareunia/itching/burning) and in lower urinary tracts symptoms evaluated with ICIQ-SF, UDI-6, IIQ-7, OABSS, and POPDI-6 (P < 0.05). Patients’ overall satisfaction regarding their sexual life, assessed via Female Sexual Function Index (FSFI), showed significant improvement in its six domains of sexual function (P < 0.05). The pH level of vaginal secretions significantly decreased. No long-term complications were found post-treatment. The Er:YAG vaginal laser procedure is associated with a significant improvement in GSM and sexual function of postmenopausal women. Our result demonstrates that it can be a safe and efficacious treatment for patients with GSM without any serious adverse effects up to 1-year post-treatment. The long-term effects of using vulvovaginal laser in the treatment of GSM should be investigated.

Portman DJ, Gass ML (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 21(10):1063–1068CrossRef

Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD (2005) Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52(Suppl 1):S46-52CrossRef

Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61(10):3090–3096PubMed

Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92(4 Pt 2):722–727PubMed

(2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9):888–902; quiz 903–884

Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M (2014) Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 124(6):1147–1156CrossRef

FDA warns against use of energy-based devices to perform vaginal rejuvenation or vaginal cosmetic procedures: FDA safety communication. https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic

Fractional Laser Treatment of Vulvovaginal Atrophy and U.S. Food and Drug Administration Clearance. https://www.acog.org/clinical-information/policy-and-position-statements/position-statements/2018/fractional-laser-treatment-of-vulvovaginal-atrophy-and-us-food-and-drug-administration-clearance

Drnovsek-Olup B, Beltram M, Pizem J (2004) Repetitive Er:YAG laser irradiation of human skin: a histological evaluation. Lasers Surg Med 35(2):146–151CrossRef

10.

Kunzi-Rapp K, Dierickx CC, Cambier B, Drosner M (2006) Minimally invasive skin rejuvenation with Erbium: YAG laser used in thermal mode. Lasers Surg Med 38(10):899–907CrossRef

11.

Bodendorf MO, Willenberg A, Anderegg U, Grunewald S, Simon JC, Paasch U (2010) Connective tissue response to fractionated thermo-ablative erbium: YAG skin laser treatment. Int J Cosmet Sci 32(6):435–445CrossRef

12.

Gaspar A, Brandi H, Gomez V, Luque D (2017) Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med 49(2):160–168CrossRef

13.

Ibinaeva IS, Apolikhina IA, Makhmedzhanova FN, Muslimova SZ (2012) ICIQ-SF questionnaire in women with urinary incontinence. Urologiia 1:38–42

14.

Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14(2):131–139CrossRef

15.

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68(2):318–323CrossRef

16.

Barber MD, Walters MD, Bump RC (2005) Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 193(1):103–113CrossRef

17.

Srisukho S, Pantasri T, Piyamongkol W, Phongnarisorn C, Morakote N (2019) The experience of genitourinary syndrome of menopause (GSM) among Thai postmenopausal women: the non-reporting issue. Int Urogynecol J 30(11):1843–1847CrossRef

18.

Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, Hershman JM, Judd HL (1983) Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 57(1):133–139CrossRef

19.

Baker VL (1994) Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 21(2):271–297CrossRef

20.

Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329(11):753–756CrossRef

21.

Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M (2018) Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric 21(2):148–152CrossRef

22.

Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62(4 Suppl 1):45–51CrossRef

23.

Salvatore S, França K, Lotti T, Parma M, Palmieri S, Candiani M, D’Este E, Viglio S, Cornaglia AI, Farina A et al (2018) Early Regenerative modifications of human postmenopausal atrophic vaginal mucosa following fractional CO(2) laser treatment. Open Access Maced J Med Sci 6(1):6–14CrossRef

24.

Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, Wajsfeld T, Fernandes CE (2018) Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 25(1):21–28CrossRef

25.

Lin KL, Chou SH, Long CY (2019) Effect of Er:YAG laser for women with stress urinary incontinence. Biomed Res Int 2019:7915813PubMedPubMedCentral

26.

Avis NE, Brockwell S, Randolph JF Jr, Shen S, Cain VS, Ory M, Greendale GA (2009) Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 16(3):442–452CrossRef

27.

Kingsberg SA, Wysocki S, Magnus L, Krychman ML (2013) Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 10(7):1790–1799CrossRef

28.

Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S (1997) Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 176(6):1270–1275 (discussion 1275-1277)CrossRef

29.

Roy S, Caillouette JC, Roy T, Faden JS (2004) Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol 190(5):1272–1277CrossRef

30.

Mitsuyuki M, Štok U, Hreljac I, Yoda K, Vižintin Z (2020) Treating vaginal laxity using nonablative Er:YAG laser: a retrospective case series of patients from 2.5 years of clinical practice. Sex Med 8(2):265–273CrossRef

31.

Gordon C, Gonzales S, Krychman ML (2019) Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause 26(4):423–427CrossRef

32.

Gambacciani M, Cervigni M, Gaspar A, NovakovMikić A, Gaviria J, Koron N, Vizintin Z (2020) Safety of vaginal erbium laser: a review of 113,000 patients treated in the past 8 years. Climacteric 23(sup1):S28-s32CrossRef

Titel: The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM)
verfasst von: Kun-Ling Lin
Shih-Hsiang Chou
Zi-Xi Loo
Yi-Yin Liu
Jung-Chien Cheng
Cheng-Yu Long
Publikationsdatum: 06.01.2022
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 4/2022
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-021-03484-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Near IR-plasmon enhanced guided fluorescence and thermal imaging of tissue subsurface target using ICG-labeled gold nanourchin and protein contrast agent: implication of stability

Effects of photobiomodulation and deep water running in patients with chronic non-specific low back pain: a randomized controlled trial

Vaginal erbium laser for treatment of stress urinary incontinence: optimization of treatment regimen for a sustained long-term effect

Treatment of carpal tunnel syndrome by low-level laser therapy versus corticosteroid injection: a randomized, prospective clinical study

Diagnosing COVID-19 in human serum using Raman spectroscopy

Erythema Ab Igne successfully treated with a 755-nm alexandrite picosecond laser